{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T19:49:06Z","timestamp":1788637746566,"version":"build-2803163510"},"reference-count":64,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.clinre.2023.102174","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T21:11:47Z","timestamp":1687813907000},"page":"102174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Effects of saroglitazar in the treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0812-2810","authenticated-orcid":false,"given":"Sanjay","family":"Bandyopadhyay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shambo Samrat","family":"Samajdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3153-4166","authenticated-orcid":false,"given":"Saibal","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinre.2023.102174_bib0001","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2023.102174_bib0002","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic fatty liver disease 2020: the state of the disease","volume":"158","author":"Cotter","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2023.102174_bib0003","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2337\/diabetes.50.8.1844","article-title":"Nonalcoholic fatty liver disease: a feature of the metabolic syndrome","volume":"50","author":"Marchesini","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.clinre.2023.102174_bib0004","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1053\/j.gastro.2012.02.003","article-title":"Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications","volume":"142","author":"Cusi","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2023.102174_bib0005","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/hep.30254","article-title":"Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2023.102174_bib0006","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMra1503519","article-title":"Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis","volume":"377","author":"Diehl","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2023.102174_bib0007","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jhep.2017.11.014","article-title":"Lipotoxicity and the gut-liver axis in NASH pathogenesis","volume":"68","author":"Marra","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2023.102174_bib0008","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.metabol.2016.05.003","article-title":"Non-alcoholic fatty liver disease and dyslipidemia: an update","volume":"65","author":"Katsiki","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.clinre.2023.102174_bib0009","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases","volume":"66","author":"Adams","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.clinre.2023.102174_bib0010","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","article-title":"Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study","volume":"155","author":"Vilar-Gomez","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2023.102174_bib0011","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0016-5085(99)70506-8","article-title":"Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity","volume":"116","author":"Matteoni","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2023.102174_bib0012","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3109\/07853890.2010.518623","article-title":"Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity","volume":"43","author":"Musso","year":"2011","journal-title":"Ann Med"},{"key":"10.1016\/j.clinre.2023.102174_bib0013","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2023.102174_bib0014","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41575-020-00366-5","article-title":"Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors","volume":"18","author":"Francque","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2023.102174_bib0015","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.semcdb.2012.01.003","article-title":"PPARs: fatty acid sensors controlling metabolism","volume":"23","author":"Poulsen","year":"2012","journal-title":"Semin Cell Dev Biol"},{"key":"10.1016\/j.clinre.2023.102174_bib0016","article-title":"Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis","volume":"111s","author":"Polyzos","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.clinre.2023.102174_bib0017","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.3390\/ijms21062061","article-title":"PPARs as metabolic regulators in the liver: lessons from liver-specific PPAR-null mice","volume":"21","author":"Wang","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clinre.2023.102174_bib0018","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s40261-013-0128-3","article-title":"Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARalpha agonist with moderate PPARgamma agonist activity in healthy human subjects","volume":"33","author":"Jani","year":"2013","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.clinre.2023.102174_bib0019","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/1932296813518680","article-title":"A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of saroglitazar 2 and 4mg compared to pioglitazone 45mg in diabetic dyslipidemia (PRESS V)","volume":"8","author":"Pai","year":"2014","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.clinre.2023.102174_bib0020","doi-asserted-by":"crossref","first-page":"e00136","DOI":"10.1002\/prp2.136","article-title":"Saroglitazar, a novel PPAR\u03b1\/\u03b3 agonist with predominant PPAR\u03b1 activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models","volume":"3","author":"Jain","year":"2015","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.clinre.2023.102174_bib0021","doi-asserted-by":"crossref","first-page":"9330","DOI":"10.1038\/s41598-020-66458-z","article-title":"The PPAR \u03b1\/\u03b3 agonist saroglitazar improves insulin resistance and steatohepatitis in a diet induced animal model of nonalcoholic fatty liver disease","volume":"10","author":"Kumar","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinre.2023.102174_bib0022","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.cgh.2009.06.007","article-title":"Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease","volume":"7","author":"Hossain","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2023.102174_bib0023","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1053\/j.gastro.2008.09.018","article-title":"Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease","volume":"135","author":"Goessling","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2023.102174_bib0024","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.clinre.2023.102174_bib0025","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.clinre.2023.102174_bib0026","unstructured":"Ottawa Hospital Research Institute [Internet]. [cited 2023 Mar 10].Available from: https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"10.1016\/j.clinre.2023.102174_bib0027","unstructured":"Higgins J., Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. http:\/\/training.cochrane.org\/handbook (accessed 25 March 2023)."},{"key":"10.1016\/j.clinre.2023.102174_bib0028","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.clinre.2023.102174_bib0029","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.clinre.2023.102174_bib0030","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jclinepi.2012.03.013","article-title":"GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations","volume":"66","author":"Andrews","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.clinre.2023.102174_bib0031","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jclinepi.2013.02.003","article-title":"GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength","volume":"66","author":"Andrews","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.clinre.2023.102174_bib0032","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/jgh3.12878","article-title":"Efficacy and safety of saroglitazar in real-world patients of non-alcoholic fatty liver disease with or without diabetes including compensated cirrhosis: a tertiary care center experience","volume":"7","author":"Chaudhuri","year":"2023","journal-title":"JGH Open"},{"key":"10.1016\/j.clinre.2023.102174_bib0033","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2023.102174_bib0034","doi-asserted-by":"crossref","first-page":"21117","DOI":"10.1038\/s41598-020-78342-x","article-title":"Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study","volume":"10","author":"Goyal","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinre.2023.102174_bib0035","first-page":"L5","article-title":"An investigator initiated prospective, single arm observational study to evaluate the safety and efficacy of saroglitazar 4mg in patients with nonalcoholic fatty liver disease (NAFLD)\/non-alcoholic steatohepatitis (NASH)","volume":"6","author":"Hajare","year":"2019","journal-title":"Int J Contemp Med Res;"},{"key":"10.1016\/j.clinre.2023.102174_bib0036","first-page":"OC21","article-title":"Role of saroglitazar in non diabetic nonalcoholic fatty liver disease patients: a retrospective observational study","volume":"15","author":"Jaiswal","year":"2021","journal-title":"J Diag Clin Res"},{"key":"10.1016\/j.clinre.2023.102174_bib0037","first-page":"e9065","article-title":"An observational study of reduction in glycemic parameters and liver stiffness by saroglitazar 4mg in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease","volume":"12","author":"Mitra","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.clinre.2023.102174_bib0038","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jceh.2021.06.015","article-title":"Saroglitazar for nonalcoholic fatty liver disease: a single centre experience in 91 patients","volume":"12","author":"Padole","year":"2022","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.clinre.2023.102174_bib0039","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jceh.2021.03.012","article-title":"Safety and efficacy of saroglitazar in nonalcoholic fatty liver patients with diabetic dyslipidemia-a prospective, interventional, pilot study","volume":"12","author":"Rajesh","year":"2022","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.clinre.2023.102174_bib0040","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/4287075","article-title":"Clinical case series of decrease in shear wave elastography values in ten diabetic dyslipidemia patients having NAFLD with saroglitazar 4\u2009mg: an Indian experience","volume":"2020","author":"Roy","year":"2020","journal-title":"Case Rep Med"},{"key":"10.1016\/j.clinre.2023.102174_bib0041","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1016\/j.cgh.2020.10.051","article-title":"A phase 2 double blinded, randomized controlled trial of saroglitazar in patients with nonalcoholic steatohepatitis","volume":"19","author":"Siddiqui","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2023.102174_bib0042","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/liv.13634","article-title":"Dual PPAR\u03b1\/\u03b3 agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models","volume":"38","author":"Jain","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.clinre.2023.102174_bib0043","doi-asserted-by":"crossref","first-page":"9330","DOI":"10.1038\/s41598-020-66458-z","article-title":"The PPAR \u03b1\/\u03b3 agonist saroglitazar improves insulin resistance and steatohepatitis in a diet induced animal model of nonalcoholic fatty liver disease","volume":"10","author":"Kumar","year":"2020","journal-title":"Sci Rep."},{"key":"10.1016\/j.clinre.2023.102174_bib0044","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40360-021-00524-8","article-title":"Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis","volume":"22","author":"Akbari","year":"2021","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.clinre.2023.102174_bib0045","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1007\/s10753-019-00967-6","article-title":"Saroglitazar deactivates the hepatic LPS\/TLR4 signaling pathway and ameliorates adipocyte dysfunction in rats with high-fat emulsion\/LPS model-induced non-alcoholic steatohepatitis","volume":"42","author":"Hassan","year":"2019","journal-title":"Inflammation"},{"key":"10.1016\/j.clinre.2023.102174_bib0046","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.2337\/diabetes.54.8.2460","article-title":"Therapeutic roles of peroxisome proliferator-activated receptor agonists","volume":"54","author":"Staels","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.clinre.2023.102174_bib0047","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1475-2840-4-14","article-title":"Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons","volume":"4","author":"Tenenbaum","year":"2005","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"10.1016\/j.clinre.2023.102174_bib0048","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2147\/DMSO.S49592","article-title":"Saroglitazar for the treatment of hypertrig-lyceridemia in patients with type 2 diabetes: current evidence","volume":"15","author":"Sosale","year":"2015","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.clinre.2023.102174_bib0049","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1517\/14656566.2015.1009894","article-title":"Saroglitazar for the treatment of dyslipidemia in diabetic patients","volume":"16","author":"Joshi","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clinre.2023.102174_bib0050","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2174\/1874467212666190111165015","article-title":"A contemporary overview of PPAR\u03b1\/\u03b3 dual agonists for the management of diabetic dyslipidemia","volume":"12","author":"Balakumar","year":"2019","journal-title":"Curr Mol Pharmacol"},{"key":"10.1016\/j.clinre.2023.102174_bib0051","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.cgh.2014.10.008","article-title":"Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile","volume":"13","author":"Siddiqui","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2023.102174_bib0052","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/lt.26069","article-title":"Atherogenic dyslipidemia after liver transplantation: mechanisms and clinical implications","volume":"27","author":"Syed","year":"2021","journal-title":"Liver Transpl"},{"key":"10.1016\/j.clinre.2023.102174_bib0053","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1002\/hep.30410","article-title":"The interplay between nonalcoholic fatty liver disease and atherosclerotic heart disease","volume":"69","author":"Patel","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2023.102174_bib0054","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1016\/j.cgh.2020.09.039","article-title":"Association between lipoprotein particles and atherosclerotic events in nonalcoholic fatty liver disease","volume":"19","author":"Patel","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2023.102174_bib0055","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12933-019-0884-3","article-title":"New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence","volume":"18","author":"Kaul","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.clinre.2023.102174_bib0056","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"NATIVE study group. A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2023.102174_bib0057","doi-asserted-by":"crossref","DOI":"10.1097\/LVT.0000000000000110","article-title":"Saroglitazar improves nonalcoholic fatty liver disease and metabolic health in liver transplant recipients","author":"Siddiqui","year":"2023","journal-title":"Liver Transpl"},{"key":"10.1016\/j.clinre.2023.102174_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2023.01.018","article-title":"Saroglitazar, a dual PPAR \u03b1\/\u03b3 agonist, improves atherogenic dyslipidemia in patients with non-cirrhotic nonalcoholic fatty liver disease: a pooled analysis","author":"Siddiqui","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2023.102174_bib0059","doi-asserted-by":"crossref","unstructured":"Kovalic A.J., Gozar M., Da B.L., Bernstein D., Satapathy S.K. Pharmacotherapeutic efficacy on noninvasive fibrosis progression in nonalcoholic fatty liver disease: a systematic review and network meta-analysis. Eur J Gastroenterol Hepatol.;35:102\u201311.","DOI":"10.1097\/MEG.0000000000002463"},{"key":"10.1016\/j.clinre.2023.102174_bib0060","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.atherosclerosis.2006.05.007","article-title":"LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"192","author":"Mora","year":"2007","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.clinre.2023.102174_bib0061","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.cgh.2022.04.022","article-title":"Liver transplant biomarker group. Interplay between dyslipidemia, atherogenic lipoproteins, and residual atherogenic risk in liver transplant recipients","volume":"21","author":"Tseng","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2023.102174_bib0062","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMra0912063","article-title":"Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease","volume":"363","author":"Targher","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2023.102174_bib0063","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.clinre.2023.102174_bib0064","first-page":"79","article-title":"Metabolic-associated Fatty Liver Disease: time to integrate ground-breaking new terminology to our clinical practice?","volume":"21","author":"Demirtas","year":"2020","journal-title":"Hepatol Forum"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740123000992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740123000992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:36:42Z","timestamp":1761896202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740123000992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":64,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S2210740123000992"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2023.102174","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of saroglitazar in the treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2023.102174","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102174"}}